Background {#Sec2}
==========

CRC is the third most common cancer in the world. It was estimated that more than one million cases and 600 thousands deaths occurred in 2012 (Torre et al. [@CR23]). The lung is known to be the second most frequent site of metastases. 19% of CRC patients were found to have synchronous metastases (present at the time of CRC diagnosis) before treatment, 11% of whom had lung metastases (Mitry et al. [@CR13]). About 2--7% of patients have isolated metastases, while about 10% of patients will have synchronous pulmonary and liver metastases (Johnston et al. [@CR8]).

Despite the lack of randomized studies, pulmonary metastasection has been recognized as a standard treatment for CRC patients with resectable pulmonary metastases. A pooled analysis of CRC pulmonary oligometastasis found that 5-year survival rate after pulmonary metastasectomy was 54.3% (Salah et al. [@CR20]). In accordance with this finding, a series of studies demonstrated an overall 5-year survival rate of approximately 30.5--54.4% after resection of pulmonary metastases (Goya et al. [@CR5]; McAfee et al. [@CR11]; McCormack et al. [@CR12]; Zampino et al. [@CR27]; Salah et al. [@CR21]). The prognostic factors of these patients included the number of pulmonary metastases, serum carcinoembryonic antigen (CEA), mediastinal and hilar lymph node involvement, and the disease-free interval (DFI) between the resection of the primary tumor and pulmonary metastases (Pfannschmidt et al. [@CR18]).

Although surgical resection significantly improves the survival of these patients, relapses are still a challenge for treatment. It has been reported that the rate of relapse after resection of colorectal metastases ranges from 20 to 68% (Welter et al. [@CR25]; Pfannschmidt et al. [@CR19]; Guerrera et al. [@CR6]). Therefore, it is still an urgent problem to find effective therapeutic strategies to reduce the risk of relapse in these patients (Brandi et al. [@CR2]). However, the role of systemic chemotherapy in these patients is still inconsistent. Only a few studies have reported that peri-operative chemotherapy contributes to survival after resection of CRC pulmonary metastases(Muñoz Llarena et al. [@CR14]; Kaira et al. [@CR9]), while other studies have showed that these patients can't benefit from systemic chemotherapy (Brandi et al. [@CR1]; Park et al. [@CR17]). A literature review of studies that examined whether peri-operative chemotherapy provided benefit for CRC patients with resection of lung metastases identified six retrospective studies (Guerrera et al. [@CR7]). Five of these studies showed that adjuvant chemotherapy did not benefit OS, while a single study showed that chemotherapy positively impacted OS. However, meta-analysis was not conducted in this review. Therefore, we performed a systematic review and meta-analysis to evaluate the effectiveness of peri-operative chemotherapy in the treatment of CRC patients receiving resection of pulmonary metastases.

Method {#Sec3}
======

Search strategy {#Sec4}
---------------

Studies were identified by searching PubMed, Cochrane Library databases, and Embase without language restriction. The systematic review was undertaken on January 21, 2018. The following terms and keywords were used: pulmonary metastasis, pulmonary metastases, lung metastases, lung metastasis, colorectal cancer, colorectal neoplasms, colorectal tumor, colorectal carcinoma, rectal cancer, colon cancer, adjuvant chemotherapy, post-operative chemotherapy, neo-adjuvant chemotherapy, and peri-operative chemotherapy. Relevant articles and abstracts were reviewed and selected based on the defined inclusion and exclusion criteria.

Inclusion criteria {#Sec5}
------------------

Articles were included if they were published reports that included patients treated with or without peri-operative chemotherapy with resectable colorectal lung metastases. Only studies that reported patient survival data were included. Patients with synchronous or metachronous lung metastasis (develop during treatment or follow-up) were included.

Exclusion criteria {#Sec6}
------------------

Studies that did not examine long-term follow-up were excluded.

Validity assessment {#Sec7}
-------------------

The quality of the selected studies was evaluated using the Newcastle--Ottawa Scale (NOS).

Data extraction {#Sec8}
---------------

The studies were independently examined by two investigators. First author, year of publication, study type, study population characteristics, number of subjects, length of follow-up, and outcomes were recorded. Publication bias was investigated by funnel plots.

Statistical analysis {#Sec9}
--------------------

Stata software was used to evaluate the overall effect of peri-operative chemotherapy on survival. The results were obtained as the hazard ratio of PFS/RFS/DFS and OS. I^2^ was used to evaluate heterogeneity across studies. A *p* value of \< 0.05 was considered statistically significant.

Results {#Sec10}
=======

To date, there have been no reports of randomized trials that compared surgery to neo-adjuvant or adjuvant chemotherapy combined with surgery.

Figure [1](#Fig1){ref-type="fig"} shows the summary profile of the search. We identified 11 potential cohort studies that examined peri-operative chemotherapy in combination with surgery for the treatment of resectable lung metastasis. Of the 11 studies, three studies were excluded because of insufficient data. Eight studies were eligible for the meta-analysis. Potential publication biases were evaluated using the funnel plot, which showed no publication bias (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1Flow chart of trial selectionFig. 2Funnel plot of the included studies

A total of 1936 patients in eight studies were evaluated in this meta-analysis, of whom 926 patients received surgery alone and 1010 patients received peri-operative chemotherapy and surgery (Guerrera et al. [@CR6], Park et al. [@CR30], Karim et al. [@CR29], Park et al. [@CR17], Shiomi et al. [@CR32], Hawkes et al. [@CR28], Kaira et al. [@CR9], Okumura et al. [@CR31]). Characteristics of the included studies are summarized in Table [1](#Tab1){ref-type="table"}. These studies were all published between 2011 and 2017. Three studies were conducted in Japan, two in Korea, one in Italy, one in Canada, and one in the United Kingdom. The sample size ranged from 51 to 785. Most studies evaluated the role of peri-operative chemotherapy after R0 (no residual disease) resection. Most patients received adjuvant chemotherapy, while others received neo-adjuvant chemotherapy or both. Chemotherapy regimens included oxaliplatin-based chemotherapy, irinotecan-based therapy, molecular targeted drugs, and 5-FU monotherapy. Chemotherapy regimen was not described in one study (Guerrera et al. [@CR6]). All studies were retrospective analyses. The quality assessment of the included studies was evaluated by NOS. The scores ranged from 7 to 9. The characteristics of the included studies contained sex and age (Table S1).Table 1Characteristics of the included studiesAuthor (year)Recruitment periodRegionCharacteristic of patientsChemotherapyChemotherapy regimenMedian follow-up (months)5-year survival (100%)Park ([@CR30])2002--2013Korea*N* = 221; Median age: 62 years (range 30--85 years); Male: 141; Female: 80;Adjuvant5-FU, TS-1, capecitabine, FOLFOX OR FOLFIRI34.764.20%Karim ([@CR29])2002--2009Canada*N* = 420; Median age: 64 years (range 17--87 years); Male: 251; Female: 169;Adjuvant and neo-adjuvantOxaliplatin-based chemotherapy, Irinotecan-based therapy OR 5-FU monotherapyNR40%Park ([@CR17])2001--2015Korea*N* = 91; Median age: 63 years (range 35--83 years); Male: 62; Female: 29;AdjuvantFOLFOX, FOLFIRI OR capecitabine4661.40%Shiomi ([@CR32])2000--2014Japan*N* = 100; Median age: 64.7 years (± 10.0 years); Male: 56; Female: 44;AdjuvantOxaliplatin-containing, Irinotecan-containing and molecular-target drugs5176%Hawkes ([@CR28])1997--2009UK*N* = 51; Median age: 63 years (range 41--78 years); Male: 30; Female: 21;Adjuvant and neo-adjuvantOxaliplatin, Irinotecan, Mitomycin, 5-FU, capecitabin alone OR molecular target drugs6072%Kaira ([@CR9])2003--2008Japan*N* = 80; Median age: 66 years (range 33--81 years); Male: 53; Female: 27;AdjuvantFOLFOX OR uracil-tegafur/leucovorin7155.80%Guerrera ([@CR6])2004--2012Italy*N* = 188; Median age: 66 years (range 58--72 years); Male: 109; Female: 79;Adjuvant and neo-adjuvantNR4553%Okumura ([@CR31])2004--2008Japan*N* = 785; Median age: 66 years (range 29--89 years); Male: 448; Female: 337;AdjuvantOxaliplatin-containin, Irinotecan-containing, 5-fluorouracil/leucovorin OR tegafur/uracil6568.10%

All eight studies that investigated OS were included for meta-analysis. The heterogeneity of the therapeutic effect was not significant (*p* = 0.404, *I*^*2*^ = 3.3%). The outcome of the random effect model of the meta-analysis revealed that treatment with peri-operative chemotherapy significantly prolonged OS in comparison to treatment with only pulmonary metastasectomy (HR 0.83, 95% CI 0.75--0.92, *p* \< 0.05) (Fig. [3](#Fig3){ref-type="fig"}). PFS/RFS/DFS was described in four studies. In these four studies, chemotherapy was performed in the post-surgical setting. The meta-analysis results suggested that peri-operative chemotherapy reduced the risk of progression or recurrence (HR 0.67, 95% CI 0.53--0.86, *p* \< 0.05) (Fig. [4](#Fig4){ref-type="fig"}). No heterogeneity was identified (*p* = 0.733, *I*^*2*^ = 0.0%). Independent prognostic factors were verified using multivariate analyses in four studies. Peri-operative chemotherapy strongly affected PFS/RFS/DFS and OS by multivariate analysis compared to surgery alone (OS: HR 0.56, 95% CI 0.36--0.86, *p* \< 0.05; PFS/RFS/DFS: HR 0.64, 95% CI 0.46--0.87, *p* \< 0.05) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). Different predictors were included in each final multivariate model, whereas all four studies adjusted for age, CEA level, tumor location, and peri-operative chemotherapy in the multivariate analysis.Fig. 3HR analysis of OS for peri-operative chemotherapy vs. surgery aloneFig. 4HR analysis of PFS/RFS/DFS for peri-operative chemotherapy vs. surgery aloneTable 2Subgroup analyses of HR of OS for peri-operative chemotherapy vs. surgery aloneStudy of subgroupChemotherapy and surgerySurgery aloneHR (95% CI)WeightMultivariate analysis Park ([@CR17])63280.47 (0.11, 2.01)8.88 Shiomi ([@CR32])42580.35 (0.14, 0.81)24.49 Guerrera ([@CR6])122660.67 (0.40, 1.15)66.62 Subtotal2271520.56 (0.36, 0.86)Heterogeneity: *I*-squared = 0.0%, *p* = 0.444R0 resection Park ([@CR30])176450.94 (0.52, 1.70)19.23 Park ([@CR17])63280.36 (0.15, 0.91)9.82 Shiomi ([@CR32])42580.64 (0.29, 1.39)12.44 Hawkes ([@CR28])38130.45 (0.19, 1.05)10.76 Okumura ([@CR31])3764090.85 (0.66, 1.09)47.74 Subtotal6955530.72 (0.53, 0.97)Heterogeneity: *I*-squared = 0.0%, *p* = 0.425Metachronous pulmonary metastases Park ([@CR17])63280.36 (0.15, 0.91)47.35 Hawkes ([@CR28])38130.45 (0.19, 1.05)52.65 Subtotal101410.40 (0.22, 0.75)Heterogeneity: *I*-squared = 0.0%, *p* = 0.725Table 3Subgroup analyses of HR of PFS/RFS/DFS for peri-operative chemotherapy vs. surgery aloneStudy of subgroupChemotherapy and surgerySurgery aloneHR (95% CI)WeightMultivariate analysis Park ([@CR30])176450.65 (0.42, 1.00)53.95 Park ([@CR17])63280.92 (0.43, 1.98)17.16 Shiomi ([@CR32])42580.49 (0.27, 0.88)28.89 Subtotal2811310.64 (0.46, 0.87)Heterogeneity: *I*-squared = 0.0%, *p* = 0.438R0 resectionPark ([@CR30])176450.69 (0.45, 1.04)44.67Park ([@CR17])63281.79 (0.52, 1.22)43.11Shiomi ([@CR32])42580.58 (0.26, 1.29)12.22Subtotal2811310.72 (0.54, 0.95)Heterogeneity: *I*-squared = 0.0%, *p* = 0.779)Metachronous pulmonary metastases Park ([@CR30])151410.57 (0.38, 0.87)51.26 Park ([@CR17])63280.79 (0.52, 1.22)48.74 Subtotal214690.67 (0.49, 0.92)Heterogeneity: *I*-squared = 13.7%, *p* = 0.282

The efficacy of peri-operative chemotherapy after pulmonary metastasectomy was further investigated in CRC patients after R0 resection. Five studies were included in the final analysis. Hawkes et al., and Okumura et al., did not report PFS/RFS/DFS data. There was a significant different benefit in the peri-operative group for OS and PFS/RFS/DFS (OS: HR 0.82, 95% CI 0.74--0.90, *p* \< 0.05; PFS/RFS/DFS: HR 0.72, 95% CI 0.54--0.95, *p* \< 0.05) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}). Three of these studies assessed OS and PFS of CRC patients with metachronous lung metastases. Hawkes et al. provided data on OS, while Park et al. supplied data on PFS/RFS/DFS. A significant improvement was confirmed in OS and PFS/RFS/DFS (OS: HR 0.40, 95% CI 0.22--0.75, *p* \< 0.05; PFS/RFS/DFS: HR 0.67, 95% CI 0.49--0.92, *p* \< 0.05) (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}).

Discussion {#Sec11}
==========

The need for peri-operative chemotherapy after pulmonary metastasectomy from CRC patients is still a matter of debate due to the lack of evidence. In this study, we evaluated eight retrospective studies concerning the efficacy of chemotherapy in these patients. The HR estimates suggested that patients benefit from peri-operative chemotherapy after resection of pulmonary metastases. For PFS/RFS/DFS, the peri-operative treatment group also improved survival. Multivariate meta-analyses were conducted to adjust for other variables that could have influenced survival, such as age, disease stage, CEA level, and tumor location. Our analyses demonstrated that peri-operative chemotherapy was an independent and favorable prognostic factor for OS and PFS/RFS/DFS, which is consistent with previous findings (Muñoz Llarena et al. [@CR14]; Guerrera et al. [@CR7]).

Surgery has become the standard treatment for CRC patients after resection of pulmonary metastases (Goya et al. [@CR5]; Mitry et al. [@CR13]; Zampino et al. [@CR27]; Van Cutsem et al. [@CR24]). Despite the recommendation of adjuvant chemotherapy after surgery for CRC patients with liver metastases (Nordlinger et al. [@CR16], Van Cutsem et al. [@CR24]), this is not the case for CRC patients with lung metastases (Brandi et al. [@CR2]; Guerrera et al. [@CR7]). "Watch and wait" is regarded to be an appropriate approach after pulmonary metastasectomy in CRC patients for lung involvement, as it may be associated with a better outcome. The different therapeutic recommendation may be due to molecular differences depending on the sites of metastases (Khattak et al. [@CR10]; Yaeger et al. [@CR26]). However, our results showed that peri-operative chemotherapy led to a significant OS and PFS/RFS/DFS benefit in CRC patients in comparison to surgery alone. We further analyzed studies that investigated R0 resection of pulmonary metastases or metachronous pulmonary metastases. Survival benefits in terms of OS and PFS were also achieved by peri-operative chemotherapy. The benefit of peri-operative chemotherapy may be influenced by the type of chemotherapy regimen received by CRC patients (Nakajima et al. [@CR15]).

There were some limitations to this study. All included studies were retrospective analyses and were associated with a low level of evidence. Compared with randomized control trials, retrospective and non-randomized studies can introduce bias into data analysis and confound the results. For example, adjuvant chemotherapy was likely proposed to a selected subgroup of patients who were fit and without serious complications after surgery, had poor prognosis, or had heavier disease burden. It is also necessary to consider the heterogeneous chemotherapy regimens used in the study. Chemotherapy regimens used in the study included intravenous 5-FU, TS-1, capecitabine, intravenous 5-FU plus oxaliplatin (FOLFOX), intravenous 5-FU plus irinotecan (FOLFIRI), and molecular targeted agents. Recently, these new chemotherapeutic regimens have significantly improved the prognosis of patients with CRC (de Gramont et al. [@CR3]; Saltz et al. [@CR22]; Goldberg et al. [@CR4]). The survival rates of patients treated with chemotherapy after resection of CRC pulmonary metastases have increased over time. This has contributed to the wide range in the efficacy of peri-operative chemotherapy in CRC patients who underwent pulmonary metastectomy. However, it is still difficult to define the chemotherapy regimens, doses, and the number of cycles of peri-operative therapy in practice.

Conclusion {#Sec100}
==========

In conclusion, our study is the first meta-analysis to assess whether peri-operative chemotherapy impacts the survival of CRC patients with resectable pulmonary metastases. Although a significant survival benefit has been observed in these patients, the conclusion is still limited by the fact that the analysis was based on retrospective studies. Randomized control studies focused on peri-operative treatment for this subgroup of patients is warranted.
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CRC

:   Colorectal cancer

HR

:   Hazard ratio

OS

:   Overall survival

PFS

:   Progression-free survival

RFS

:   Recurrence-free survival

DFS

:   Disease-free survival

CEA

:   Carcinoembryonic antigen

DFI

:   Disease-free interval

NOS

:   Newcastle--Ottawa Scale

FOLFOX

:   Intravenous 5-FU plus oxaliplatin

FOLFIRI

:   Intravenous 5-FU plus irinotecan
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